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To the Editor:
Percutaneous coronary intervention (PCI) may induce a variable
amount of myocardial necrosis. It is now well accepted that in-
creased blood levels of the plasma inflammatory marker secretory
phospholipase A2 (sPLA2) correlate with cardiac injury in patients
undergoing PCI,1 and a role for sPLA2 in PCI-related cardiac injury
has been hypothesized. Using the sPLA2 inhibitor varespladib,
Dzavik et al2 tested this hypothesis in the sPLA2 Inhibition to
Decrease Enzyme Release after Percutaneous Coronary Intervention
(SPIDER-PCI) trial. However, their results did not support a cardio-
protective effect of varespladib in patients after PCI, as was
concluded from the course of plasma levels of creatine kinase-MB
and troponin I in patients undergoing PCI with or without sPLA2
inhibitor treatment.
However, we are not convinced that the patient cohort studied was
suitable to test the hypothesis that sPLA2 is involved in PCI-related
cardiac inflammatory injury. Unlike Liu et al,1 in this SPIDER-PCI
cohort, no increase in sPLA2 blood levels was recorded in the placebo
group, and only modest C-reactive protein responses were observed.
Hence, it can be argued that, although varespladib induced an almost
complete inhibition of circulating sPLA2 activity, the drug had no effect
on the release of markers of myonecrosis, because the inflammatory
damage to the heart was marginal in this patient cohort.
Dzavik et al refer to our previous studies for evidence of the
involvement of sPLA2 in cardiac injury.3,4 However, in these studies,
the cardiotoxic role of sPLA2 was investigated in relation to acute
myocardial infarction in which acute-phase blood levels of sPLA2
may increase 10- to 100-fold. For example, levels of this enzyme can
be 200 ng/mL 48 hours after the onset of infarction,5 which is in
sharp contrast to the levels of 2 to 7 ng/mL observed in the study by
Dzavik et al. Although we cannot exclude the possibility that sPLA2
in the levels described after PCI can have cardiotoxic effects, so far,
evidence for this is lacking.
Thus, although the study by Dzavik et al suggests a limited, if any,
cardioprotective role of sPLA2 inhibition in patients undergoing PCI
with normal plasma levels of the enzyme, the cardioprotective effect
of sPLA2 inhibition in patients with acute-phase levels remains to be
established. Hence, we suggest that the hypothesis on the cardiopro-
tective activity of sPLA2 inhibitors be tested in patients developing
an acute-phase response following PCI, or in patients with acute
myocardial infarction.
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